GC1102

Hepatitis B immunoglobulin, recombinant · Green Cross Corporation

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for GC1102, covering 2016-06-30 to 2020-01-30. Get the full timeline:

Most recent: Clinical Trial Update: HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 [Phase 2, Phase 3]